ASH 2024 – J&J mounts its first-line menin challenge
The group presents data with bleximenib plus chemo, but looks behind Kura’s contender.
ASH 2024 – Sumitomo joins the menin party
Enzomenib might be the most promising agent so far, on a cross-trial basis.
Relay passes on the lirafugratinib baton
The US subsidiary of South Korea’s HLB will take on the selective FGFR2 inhibitor.
FDA red and green lights: November 2024
Autolous, Syndax, Jazz and Shorla get US approvals in a quiet month.
A combination Revolution
Amid a KRAS data dump, a doublet of RMC-6236 and RMC-6291 was a highlight.
Nerviano becomes a targeted PARP player
Two cast-offs comprise the private group's attempts to hit PARP1 and PARP7.
Truqap could fill a prostate cancer gap
The AKT inhibitor prevails in hormone-sensitive disease, but other studies have been delayed.
